Recombinant Human DEFA3, N-GST

Description of Recombinant Human DEFA3, N-GST

Introduction

Recombinant Human DEFA3, also known as human defensin alpha 3, is a small, cationic protein that plays a crucial role in the innate immune response against microbial infections. It is one of the many defensin proteins found in humans, which are known for their antimicrobial and immunomodulatory properties. In this article, we will delve into the structure, activity, and applications of recombinant human DEFA3.

Structure of Recombinant Human DEFA3

Recombinant Human DEFA3 is a 29 amino acid long protein, with a molecular weight of approximately 3.5 kDa. It is a member of the alpha-defensin family, which is characterized by a six-cysteine motif that forms three disulfide bonds. The three-dimensional structure of recombinant human DEFA3 is highly conserved, with a beta-sheet structure stabilized by the three disulfide bonds. This unique structural feature allows the protein to maintain its stability and function in various environments.

Activity of Recombinant Human DEFA3

Recombinant Human DEFA3 exhibits potent antimicrobial activity against a wide range of microorganisms, including bacteria, fungi, and viruses. It exerts its antimicrobial effects by disrupting the cell membrane of these pathogens, leading to cell lysis and death. In addition to its antimicrobial activity, recombinant human DEFA3 also has immunomodulatory properties. It can stimulate the production of pro-inflammatory cytokines and chemokines, which are essential for recruiting immune cells to the site of infection. This dual activity of recombinant human DEFA3 makes it a powerful weapon in the fight against infectious diseases.

Applications of Recombinant Human DEFA3

The unique properties of recombinant human DEFA3 make it a promising candidate for various applications in the field of medicine and biotechnology.

Antimicrobial Agent

Due to its potent antimicrobial activity, recombinant human DEFA3 can be used as an alternative to traditional antibiotics. With the rise of antibiotic-resistant bacteria, there is a growing need for new antimicrobial agents, and recombinant human DEFA3 has shown promising results in this regard. It has been tested against various drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE), and has shown strong inhibitory effects.

Therapeutic Agent for Inflammatory Diseases

Recombinant human DEFA3’s immunomodulatory properties make it a potential therapeutic agent for inflammatory diseases. It has been shown to reduce inflammation in various models of inflammatory diseases, such as colitis, arthritis, and psoriasis. It does so by regulating the production of pro-inflammatory cytokines and chemokines, thereby reducing the recruitment of immune cells to the site of inflammation.

Adjuvant in Vaccine Development

Recombinant human DEFA3 has been studied as an adjuvant in vaccine development. Adjuvants are substances that enhance the immune response to a vaccine, making it more effective. Recombinant human DEFA3 has been shown to enhance the immune response to various vaccines, including influenza and hepatitis B vaccines. This makes it a potential candidate for use in future vaccine formulations.

Diagnostic Tool for Infectious Diseases

Recombinant human DEFA3 can also be used as a diagnostic tool for infectious diseases. Its antimicrobial activity against a wide range of pathogens makes it a potential candidate for detecting and identifying these microorganisms. It has been tested in various diagnostic assays, and its ability to detect and differentiate between different pathogens has been demonstrated.

Research Tool

Recombinant human DEFA3 is also